Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JK-05
- Development stage
- Unknown
- Lead developer
- Sihuan Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**JK-05** is a small-molecule antiviral drug developed by China's Academy of Military Medical Science (AMMS) as a potential treatment for Ebola virus disease (EVD). It acts as a broad-spectrum antiviral, likely mimicking the mechanism of favipiravir (T-705) by inhibiting viral RNA polymerase, though its exact chemical formula remains undisclosed. Approved in mainland China for emergency and military use only after pre-clinical testing and safety evaluations, Sihuan Pharmaceutical acquired commercialization rights to further develop it; thousands of doses were shipped to West Africa during the 2014 outbreak for potential use in Chinese health workers.[1][3]
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on JK-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JK-05.